BactiQuant AS (OCSE:BACTIQ) YoY EBITDA Growth: 49.74% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:BACTIQ BactiQuant AS OCSE:BACTIQ
52 GF Score
Price kr2.10
GF Value kr2.64
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BactiQuant AS YoY EBITDA Growth?

BactiQuant AS OCSE:BACTIQ +0.47% 52 YoY EBITDA Growth is 49.74% as of Jun. 2026. GuruFocus rates OCSE:BACTIQ with a GF Score™ of 52/100 and a GF Value™ of kr2.64 (Modestly Undervalued). The stock has 4 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. BactiQuant AS's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 49.74%.

BactiQuant AS's EBITDA per Share for the six months ended in Jun. 2026 was kr-0.10.

BactiQuant AS YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for BactiQuant AS's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BactiQuant AS YoY EBITDA Growth Chart

BactiQuant AS Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial -631.25 -0.86 18.31 7.68 10.34

BactiQuant AS Semi-Annual Data
Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only -12.92 23.64 19.92 -3.57 49.74
OCSE:BACTIQ
52GF Score
BactiQuant AS OCSE:BACTIQ
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BactiQuant AS YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

BactiQuant AS's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.399--0.445)/ | -0.445 |
=10.34 %

BactiQuant AS's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.095--0.189)/ | -0.189 |
=49.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 49.74% mean?
BactiQuant AS (OCSE:BACTIQ) has a YoY EBITDA Growth of 49.74% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for BactiQuant AS and its competitors.
Is BactiQuant AS's YoY EBITDA Growth too high?
BactiQuant AS's current YoY EBITDA Growth is 49.74%. Overall, BactiQuant AS has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BactiQuant AS's YoY EBITDA Growth compare to VLTO and ZWS?
BactiQuant AS's YoY EBITDA Growth of 49.74% can be compared against companies in the Industrial Products industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for an Industrial Products company?
A good YoY EBITDA Growth depends on the Industrial Products industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for BactiQuant AS and its competitors. BactiQuant AS's current YoY EBITDA Growth is 49.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BactiQuant AS stock overvalued right now?
Based on GuruFocus' analysis, BactiQuant AS (OCSE:BACTIQ) is currently considered Modestly Undervalued. The stock's GF Value™ is kr2.64, compared to a current price of kr2.10 — trading 20.5% below its estimated fair value. The current YoY EBITDA Growth is 49.74%. BactiQuant AS's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For BactiQuant AS (OCSE:BACTIQ), the current YoY EBITDA Growth is 49.74% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BactiQuant AS (OCSE:BACTIQ) Overvalued in 2026?

Based on GuruFocus' analysis, BactiQuant AS stock appears to be undervalued. The current stock price of kr2.10 is trading 20.5% below its estimated GF Value™ of kr2.64. GuruFocus considers BactiQuant AS to be Modestly Undervalued.

Key valuation signals for OCSE:BACTIQ:

  • YoY EBITDA Growth: 49.74%
  • GF Value™: kr2.64 vs. price of kr2.10 (20.5% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the OCSE:BACTIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BactiQuant AS Business Description

Address Blokken 75, Birkeroed, DNK, DK-3460
BactiQuant AS focuses on delivering technology that ensures optimum usage and handling of water around the world. The company's activities include the development, production, sale and service of BactiQuant Online and BactiQuant Mobile Lab with associated test kits/substrate for the quantification and detection of bacteria in water. Its segments are Aquaculture, Data Centres, Oil & Gas, Water Utility, Industry, and Pharma. The group's products are BQ Online 2.0 PRO, BQ Online, BQ Mobile Lab, and Analysis Kits.
52GF Score

Get the complete analysis for OCSE:BACTIQ

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.10
Price
kr2.64
GF Value